• Novartis v. Eli Lilly (N.D. Cal., E.D. Va., 4th Cir., 9th Cir., and ex-U.S.). Represented Eli Lilly & Co. in global litigations, serving as U.S. counsel in 28 U.S.C. § 1782 discovery actions for use in foreign proceedings, and strategic co-counsel in multiple European litigations and European Patent Office proceedings that arose from the sale of a patent portfolio from Genentech, Inc. to Novartis Pharma AG. In October 2022, Novartis and Lilly entered into a global settlement agreement that concluded the dispute between the parties.
    • Par Pharmaceutical, Inc. et al. v. Cipla Limited, et al. (D.N.J.). Representing Par Pharmaceutical in a Hatch-Waxman case filed against generic companies involving Par's VASOSTRICT® product. Case is ongoing.
    • Jazz Pharmaceuticals, Inc. v. Synchrony Group, LLC et al. (E.D. Pa.). Represented Jazz Pharmaceuticals in a trade secret dispute regarding industry knowledge provided confidentially to marketing agent. Case settled.
    • Represented life sciences consulting firm in trade secret and copyright litigation. Settled favorably to client.
    • Endo Pharmaceuticals Inc. vs. Teva Pharmaceuticals USA, Inc., et al. (D. Del.). Trial counsel representing Endo Pharmaceuticals in numerous Hatch-Waxman patent infringement case regarding Endo's OPANA® ER controlled-release oxymorphone product against seven generic pharmaceutical manufacturers. Obtained verdict of infringement and validity, which were affirmed by the Federal Circuit.
    • SCA Hygiene Products v. First Quality Baby Products (S. Ct.). Member of Dechert team which successfully represented SCA Hygiene Products before the U.S. Supreme Court in a 7-1 decision to overturn 100 years of precedent and bar the defense of laches to claims for patent damages.
    • Endo Pharmaceuticals v. Teva, et al. (S.D.N.Y.). Trial counsel for Endo Pharmaceuticals in Hatch-Waxman Act case filed against a dozen ANDA filers involving Endo's OPANA® ER product. Following a five-week trial, the court ruled in Endo's favor, finding its patents valid and infringed. The Federal Circuit affirmed.
    • Endo Pharmaceuticals Inc., et al. v. Watson Laboratories, Inc., Mylan, Noven and TWi (D. Del.). Trial counsel for Endo Pharmaceuticals Inc. and Teikoku Seiyaku Co. Ltd. in ANDA litigation against Paragraph IV filers, involving the Lidoderm® patch. Following a six-day bench trial against Watson, the first-filer, that case was settled. Other related cases settled before trial.
    • Endo Pharmaceuticals v. Impax, Actavis, Barr, Sandoz, Watson and Roxane (D.N.J.). Represented Endo Pharmaceuticals Inc. in Hatch-Waxman Act ANDA cases filed against six generic companies involving Endo’s branded oxymorphone extended release tablet (OPANA® ER), two of which went to trial. Case settled during trial.
    • Stiefel Laboratories v. Perrigo (D. Del.). Represented GlaxoSmithKline entities in an ANDA case relating to ROGAINE® Foam. Case settled. 
    • Represented pharmaceutical giant Pfizer in patent matters relating to Pfizer’s animal health business, one of the largest in the world.
    • Represented confidential clients in the pharmaceutical sector involving trade secret misappropriation.
    • Managing IP Life Sciences Forum — Virtual (June 16-17, 2021)
      Speaker, “Litigation Case Law Developments – Federal Circuit and District Court”
    • ChIPs (Chiefs of Intellectual Property), Philadelphia Chapter
    • Philadelphia Intellectual Property Law Association